Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.
Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.
在11月9日FDA Adcom會議之前發佈簡報文件後，Veru的股價上漲，VERU的候選新冠肺炎治療方案。
Veru shares are trading higher following publication of briefing documents ahead of the Nov. 9 FDA Adcom meeting for its COVID-19 treatment candidate.
在11月9日FDA為其新冠肺炎候選藥物舉行的Adcom會議之前，Veru的股價在簡報文件公佈後走高。